Welcome to our dedicated page for Nanoviricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on Nanoviricides stock.
Nanoviricides, Inc. (NNVC) is a clinical-stage biopharmaceutical company pioneering antiviral therapies using proprietary nanomedicine technology. This page serves as the definitive source for verified news and official updates regarding the company's innovative drug development programs.
Investors and researchers will find comprehensive coverage of NNVC's progress including clinical trial developments, regulatory milestones, and strategic partnerships. Our curated collection features press releases on lead candidate NV-387's advancement through clinical studies, updates on broad-spectrum antiviral research, and collaborations advancing nanoviricide platforms.
Key content categories include scientific breakthroughs in host-mimetic nanotechnology, FDA regulatory communications, financial reporting disclosures, and analysis of NNVC's position within the antiviral therapeutics market. All materials are sourced directly from company filings and authorized statements to ensure reliability.
Bookmark this page for streamlined access to NNVC's latest developments in nanoscale antiviral solutions. Check regularly for updates on clinical programs targeting respiratory viruses, herpes-related infections, and other viral pathogens through NNVC's novel therapeutic approach.
NanoViricides announced that its antiviral drug candidate, NV-387, showed complete survival in mice lethally infected with RSV (Respiratory Syncytial Virus) in a recent study.
The study compared NV-387 with the currently approved RSV treatment, ribavirin. While NV-387 led to the complete survival of animals over a 21-day period, ribavirin resulted in the death of all subjects by day 14.
RSV is a major cause of hospitalizations and deaths among children under 5 and adults over 65. The company's NV-387 is aimed to provide a safer and more effective treatment option for these vulnerable groups.
The company has completed Phase 1a/1b human clinical trials for NV-387 with no reported adverse events and plans to advance to Phase II trials for RSV treatment.
NanoViricides, Inc. (NYSE American:NNVC) announces participation in the EF Hutton Annual Global Conference on May 15, 2024, in New York City. The Company's President will discuss progress, particularly the promising antiviral drug NV-387. Successful completion of Phase 1a/1b clinical trials with no adverse events on healthy subjects indicates excellent safety. NV-387 demonstrates strong antiviral activity against various viruses and could potentially treat Coronaviruses, RSV, and Influenza A. Plans for Phase II trials and a pipeline of drug candidates are underway.
NanoViricides, Inc. announces NV-387, a novel broad-spectrum antiviral with activity against Smallpox/Mpox. NV-387 shows strong orthopoxvirus activity against Smallpox/Mpox, both inhalation and skin abrasion modes. Animal studies demonstrate increased survival compared to tecovirimat, approved for Smallpox. NV-387 potentially reduces tecovirimat resistance. NanoViricides focuses on developing antiviral nanomedicines for various viral infections.
NanoViricides, Inc. announces the development of NV-387, a broad-spectrum antiviral drug with strong activity against Influenza A viruses, potentially including Bird Flu H5N1 virus. In a study, NV-387 showed superior antiviral effects compared to three approved anti-influenza drugs. The company believes that NV-387 may have significant potential in treating various respiratory viruses.
NanoViricides, Inc. (NNVC) reports successful completion of Phase I NV-387 Clinical Trial in India. NV-387 has shown broad-spectrum antiviral activity against various viruses. Data lock is expected soon for further analysis. Plans for Phase II trials in progress, targeting RSV infections in adults, infants, and children. The potential market size for RSV therapeutics is estimated at $8.73 billion by 2031. NanoViricides' platform technology reduces the likelihood of viruses escaping treatment.
FAQ
What is the current stock price of Nanoviricides (NNVC)?
What is the market cap of Nanoviricides (NNVC)?
